TherapeuticsMD (TXMD) EBIAT: 2010-2025
Historic EBIAT for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to $152,000.
- TherapeuticsMD's EBIAT rose 124.96% to $152,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $171,000, marking a year-over-year increase of 105.04%. This contributed to the annual value of -$2.3 million for FY2024, which is 77.51% up from last year.
- Per TherapeuticsMD's latest filing, its EBIAT stood at $152,000 for Q3 2025, which was down 72.41% from $551,000 recorded in Q2 2025.
- TherapeuticsMD's EBIAT's 5-year high stood at $159.4 million during Q4 2022, with a 5-year trough of -$49.0 million in Q1 2022.
- Moreover, its 3-year median value for EBIAT was -$809,000 (2024), whereas its average is -$1.1 million.
- Its EBIAT has fluctuated over the past 5 years, first spiked by 470.99% in 2022, then plummeted by 102.15% in 2023.
- Quarterly analysis of 5 years shows TherapeuticsMD's EBIAT stood at -$43.0 million in 2021, then soared by 470.99% to $159.4 million in 2022, then plummeted by 100.55% to -$883,000 in 2023, then soared by 113.70% to $121,000 in 2024, then spiked by 124.96% to $152,000 in 2025.
- Its last three reported values are $152,000 in Q3 2025, $551,000 for Q2 2025, and -$653,000 during Q1 2025.